Amgen presents interim overall survival data from Phase 3 study of Talimogene Laherparepvec in patients with metastatic melanoma
18 November 2013 | By Amgen
Differences in survival rates were pronounced in the subset of patients with stage IIIB, IIIC or IV M1a disease...